Endocrinological Evaluations of a Neurofibromatosis Type 1 Cohort: Is it Necessary to Evaluate Autoimmune Thyroiditis in Neurofibromatosis Type 1?

Yıl 2017, Cilt: 34 Sayı: 6, 522 - 526, 01.11.2017

Serhat Güler Gözde Yeşil Hasan Önal

Öz

Background: Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder in which the coexistence of autoimmune thyroiditis and thyroid gland tumours has been reported previously. Aims: To determine the thyroid function and autoimmune thyroid diseases in neurofibromatosis type 1 patients in order to identify the possible association between neurofibromatosis type 1 and thyroid diseases.Study Design: Case-control study.Methods: The study includes 78 consecutive patients diagnosed with neurofibromatosis type 1 between June 2010 and June 2014 and 50 healthy controls. Baseline demographic data were generated from patient examination record forms, including age, sex, height, and weight, as well as levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, anti-thyroid peroxidase and anti-thyroglobulin levels.Results: Mean age, sex, and body mass index were similar in both groups (p>0.05). The mean levels of free triiodothyronine, free thyroxine, and thyroid-stimulating hormone were not statistically different between the neurofibromatosis type 1 and control groups. Similarly, no statistically significant difference was observed between the neurofibromatosis type 1 and control groups for anti-thyroid peroxidase and anti-thyroglobulin positivity (2.5% vs 0%, p>0.05).Conclusion: Screening for autoimmune thyroid disease and thyroid function seems to be unnecessary in patients with neurofibromatosis type 1.

Anahtar Kelimeler

Neurofibromatosis 1, thyroid hormones, autoimmune thyroiditis, anti-thyroglobulin antibody, anti-thyroid peroxidase antibody

Kaynakça

• 1. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990;62:187-92.
• 2. Ingram DA, Zhang L, McCarthy J, Wenning MJ, Fisher L, Yang FC, et al. Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell developmentand function. Blood 2002;100:3656-62.
• 3. Yalcin B, Tamer E, Gür G, Oztas P, Polat MU, Alli N. Neurofibromatosis 1/Noonan syndrome associated with Hashimoto's thyroiditis and vitiligo. Acta Derm Venereol 2006;86:80-1.
• 4. Cotesta D, Erlic Z, Petramala L, Verrienti A, Cavallaro G, Giustini S, et al. Coincidence of neurofibromatosis type 1 and multiple endocrine neoplasia type 2 (MEN 2). Endocrinologist 2008;18:277-81.
• 5. Ciardi A, Pecorella I, Trombetta G, Memeo L, Quarto AD, Tondo UD. An Unusual Case of Neurofibroma of the Thyroid Capsule. Pathol Oncol Res 1997;3:293-5.
• 6. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md, USA, July 13-15, 1987 Neurofibromatosis 1988;1:172-8.
• 7. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
• 8. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
• 9. Nabi J. Neurofibromatosis Type 1 Associated with Hashimoto's Thyroiditis: Coincidence or Possible Link. Case Rep Neurol Med 2013;2013:1-4.
• 10. Bolko P, Wasko R, Waligórska J, Narozna J, Sowióski J. [Graves' disease and hyperprolactinemia in a patient with Noonan syndrome neurofibromatosis type 1]. Ann Endocrinol (Paris) 2004;65:121-4.
• 11. Ercolino T, Lai R, Giachè V, Melchionda S, Carella M, Delitala A, et al. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes. Gene 2014;536:332-5.
• 12. Kim BK, Choi YS, Gwoo S, Park YH, Yang SI, Kim JH. Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. J Med Case Rep 2012;6:179.
• 13. Doulias T, Papaziogas B, Rosser JH, Koutelidakis I. Thyroid neurofibroma in a female patient with neurofibromatosis type I: report of a case. BMJ Case Rep 2013;2013:bcr2012008216.
• 14. A.AbbasA,LichtmanAH.Disease caused by immuneresponses: hypersensitivity and autoimmunity. In: Abbas A, Lichtman AH, editors. Cellular and Molecular Immunology. Saunders, Philadelphia: Pa, USA, 2005, 5th ed. 2005:411-31.
• 15. Nanda A. Autoimmune diseases associated with neurofibromatosis type 1. Pediatr Dermatol 2008;25:392-3.
• 16. Sasazawa DT, Tsukumo DM, Lalli CA. Myxedema coma in a patient with type 1 neurofibromatosis: rare association. Arq Bras Endocrinol Metabol 2013;57:743-7.
• 17. Faraz A, Nafees T, Ahmed SA, Rizvi SS. Autoımmune hypothyroidism in patient with neurofibromatosis-1. J Ayub Med Coll Abbottabad 2015;27:938-9.
• 18. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 1997;26:189-218.
• 19. Sakane N, Shirakata S, Jin MB, Torii T, Yoshida T. Von Recklinghausen's disease with hyperthyroidism. Intern Med 1997;36:938.
• 20. Demirbilek H, Küpeli S, Özbek MN, Saygı S, Yıldırım AT. Neurofibromatosis Type 1 and Autoimmune Hyperthyroidism in a 10.5 Years-Old Girl. Cukurova Medical Journal 2013;38:805-8.
• 21. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-38.
• 22. Monzani A, Prodam F, Rapa A, Moia S, Agarla V, Bellone S. Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review. Eur J Endocrinol 2012;168:1-11.
• 23. Rapa A, Monzani A, Moia S, Vivenza D, Bellone S, Petri A, et al. Subclinical hypothyroidism in children and adolescents: a wide range of clinical, biochemical, and genetic factors involved. J Clin Endocrinol Metab 2009;94:2414-20.
• 24. Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab 2003;16:289-92.
• 25. Soucy EA, van Oppen D, Nejedly NL, Gao F, Gutmann DH, Hollander AS. Height assessments in children with neurofibromatosis type 1. J Child Neurol 2013;28:303-7.
• 26. HegedusB,YehTH,Lee daY,EmnettRJ,LiJ,GutmannDH.Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet 2008;17:2956-66.